MedTrace Logo

DDI Between BI Empagliflozin (10773) and Verapamil

NCT01276301 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-06-17

Study results available
· View outcomes & findings →

Summary

Relative bioavailability of BI 10773 given alone and together with verapamil

Conditions

  • Healthy

Interventions

DRUG

Verapamil

single dose verapamil

DRUG

BI 10773

single dose BI 10773

DRUG

BI 10773

single dose BI 10773

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276301 on ClinicalTrials.gov